Trial Outcomes & Findings for Etanercept (Enbrel®) in Psoriasis - Pediatrics (NCT NCT00078819)

NCT ID: NCT00078819

Last Updated: 2019-07-29

Results Overview

The percentage of participants who achieved 75% or greater improvement (decrease) from baseline in PASI score after 12 weeks of treatment. The PASI score is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Participants who entered the escape arm or had missing data at week 12 were considered non-responders.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 211 participants
• Primary outcome timeframe: Baseline and week 12
• Results posted on: 2019-07-29

Participant Flow

This 48-week study was conducted at 42 sites in the United States and Canada. The first participant was enrolled on September 8, 2004, and the last participant on November 29, 2005.

On enrollment, participants underwent randomization at a 1:1 ratio by an interactive voice-response system.

Participant milestones

Measure	Placebo Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12. Participants (including those who escaped to etanercept) received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36). Participants who did not achieve PASI 50 at week 24 or PASI 75 at week 36 (incomplete response) could discontinue the study or continue to receive open-label etanercept with a topical standard-of-care until week 48.	Etanercept Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a more than 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12. Participants (including those who escaped to etanercept) received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36). Participants who did not achieve PASI 50 at week 24 or PASI 75 at week 36 (incomplete response) could discontinue the study or continue to receive open-label etanercept with a topical standard-of-care until week 48.	Withdrawal/Re-treatment Period: Placebo At week 36, participants with a PASI 75 response were re-randomized to receive placebo once a week for 12-weeks in the double-blind withdrawal period (weeks 37 to 48). Participants who relapsed (defined as a loss of PASI 75 response) were to resume open-label treatment with 0.8 mg/kg etanercept once a week until week 48 (re-treatment period).	Withdrawal/Re-treatment Period: Etanercept At week 36, participants with a PASI 75 response were re-randomized to receive 0.8 mg/kg etanercept once a week for 12-weeks in the double-blind, withdrawal period (weeks 37 to 48). Participants who relapsed (defined as a loss of PASI 75 response) were to resume open-label treatment with 0.8 mg/kg etanercept once a week until week 48 (re-treatment period).
Double-blind Treatment Period: Week 1-12 STARTED	105	106	0	0
Double-blind Treatment Period: Week 1-12 Entered Escape	27	5	0	0
Double-blind Treatment Period: Week 1-12 COMPLETED	104	105	0	0
Double-blind Treatment Period: Week 1-12 NOT COMPLETED	1	1	0	0
Open-label Treatment Period: Weeks 13-36 STARTED	103	105	0	0
Open-label Treatment Period: Weeks 13-36 COMPLETED	63	75	0	0
Open-label Treatment Period: Weeks 13-36 NOT COMPLETED	40	30	0	0
Withdrawal Period: Weeks 37-48 STARTED	0	0	69	69
Withdrawal Period: Weeks 37-48 Received Study Drug	0	0	69	68
Withdrawal Period: Weeks 37-48 COMPLETED	0	0	40	55
Withdrawal Period: Weeks 37-48 NOT COMPLETED	0	0	29	14
Re-treatment Period STARTED	0	0	29	13
Re-treatment Period Received Study Drug	0	0	30	12
Re-treatment Period COMPLETED	0	0	29	13
Re-treatment Period NOT COMPLETED	0	0	0	0

Reasons for withdrawal

Measure	Placebo Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12. Participants (including those who escaped to etanercept) received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36). Participants who did not achieve PASI 50 at week 24 or PASI 75 at week 36 (incomplete response) could discontinue the study or continue to receive open-label etanercept with a topical standard-of-care until week 48.	Etanercept Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a more than 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12. Participants (including those who escaped to etanercept) received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36). Participants who did not achieve PASI 50 at week 24 or PASI 75 at week 36 (incomplete response) could discontinue the study or continue to receive open-label etanercept with a topical standard-of-care until week 48.	Withdrawal/Re-treatment Period: Placebo At week 36, participants with a PASI 75 response were re-randomized to receive placebo once a week for 12-weeks in the double-blind withdrawal period (weeks 37 to 48). Participants who relapsed (defined as a loss of PASI 75 response) were to resume open-label treatment with 0.8 mg/kg etanercept once a week until week 48 (re-treatment period).	Withdrawal/Re-treatment Period: Etanercept At week 36, participants with a PASI 75 response were re-randomized to receive 0.8 mg/kg etanercept once a week for 12-weeks in the double-blind, withdrawal period (weeks 37 to 48). Participants who relapsed (defined as a loss of PASI 75 response) were to resume open-label treatment with 0.8 mg/kg etanercept once a week until week 48 (re-treatment period).
Double-blind Treatment Period: Week 1-12 Adverse Event	0	1	0	0
Double-blind Treatment Period: Week 1-12 Withdrawal by Subject	1	0	0	0
Open-label Treatment Period: Weeks 13-36 Lost to Follow-up	1	1	0	0
Open-label Treatment Period: Weeks 13-36 Adverse Event	3	2	0	0
Open-label Treatment Period: Weeks 13-36 Withdrawal by Subject	2	2	0	0
Open-label Treatment Period: Weeks 13-36 Incomplete Responders	34	25	0	0
Withdrawal Period: Weeks 37-48 Entered Retreatment	0	0	29	13
Withdrawal Period: Weeks 37-48 Lost to Follow-up	0	0	0	1

Baseline Characteristics

Etanercept (Enbrel®) in Psoriasis - Pediatrics

Baseline characteristics by cohort

Measure	Placebo n=105 Participants Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12).	Etanercept n=106 Participants Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12).	Total n=211 Participants Total of all reporting groups
Age, Continuous	13.00 years n=5 Participants	14.00 years n=7 Participants	13.00 years n=5 Participants
Age, Customized 4 to 11 years	38 Participants n=5 Participants	38 Participants n=7 Participants	76 Participants n=5 Participants
Age, Customized 12 to 17 years	67 Participants n=5 Participants	68 Participants n=7 Participants	135 Participants n=5 Participants
Sex: Female, Male Female	52 Participants n=5 Participants	51 Participants n=7 Participants	103 Participants n=5 Participants
Sex: Female, Male Male	53 Participants n=5 Participants	55 Participants n=7 Participants	108 Participants n=5 Participants
Race/Ethnicity, Customized White	75 Participants n=5 Participants	83 Participants n=7 Participants	158 Participants n=5 Participants
Race/Ethnicity, Customized Black or African American	8 Participants n=5 Participants	3 Participants n=7 Participants	11 Participants n=5 Participants
Race/Ethnicity, Customized Hispanic or Latino	14 Participants n=5 Participants	8 Participants n=7 Participants	22 Participants n=5 Participants
Race/Ethnicity, Customized Asian	6 Participants n=5 Participants	9 Participants n=7 Participants	15 Participants n=5 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants
Race/Ethnicity, Customized Other	2 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants
Duration of Psoriasis	5.80 years n=5 Participants	6.80 years n=7 Participants	5.90 years n=5 Participants
Psoriasis Area and Severity Index (PASI)	16.40 units on a scale n=5 Participants	16.70 units on a scale n=7 Participants	16.40 units on a scale n=5 Participants

PRIMARY outcome

Timeframe: Baseline and week 12

Population: The intent-to-treat population included all randomized participants.

The percentage of participants who achieved 75% or greater improvement (decrease) from baseline in PASI score after 12 weeks of treatment. The PASI score is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Participants who entered the escape arm or had missing data at week 12 were considered non-responders.

Outcome measures

Measure	Placebo n=105 Participants Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Etanercept n=106 Participants Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a more than 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Escape: Etanercept Participants with a \> 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, escaped to etanercept 0.8 mg/kg once a week up to week 12.
Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12	11.0 percentage of participants	57.0 percentage of participants	—

SECONDARY outcome

Timeframe: Baseline and week 12

Population: Intent-to-treat population

The percentage of participants who achieved 50% or greater improvement from baseline in PASI score after 12 weeks of treatment. PASI is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Participants who entered the escape arm or had missing data at week 12 were considered non-responders.

Outcome measures

Measure	Placebo n=105 Participants Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Etanercept n=106 Participants Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a more than 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Escape: Etanercept Participants with a \> 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, escaped to etanercept 0.8 mg/kg once a week up to week 12.
Percentage of Participants Achieving a ≥ 50% Improvement in PASI Score (PASI 50) at Week 12	23 percentage of participants	75 percentage of participants	—

SECONDARY outcome

Timeframe: Week 12

Population: Intent-to-treat population

The sPGA is a static measurement based on induration, erythema, and scaling. The sPGA is assessed on a scale from 0 to 5:

0 = clear (no evidence of plaque elevation, erythema or scaling)

1. = almost clear (minimal plaque elevation, erythema or scaling)

2. = mild (mild plaque elevation or scaling, light red coloration)

3. = moderate (moderate plaque elevation, scaling, light red coloration)

4. = marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)

5. = severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).

Participants who entered the escape arm or had missing data at week 12 were considered non-responders.

Outcome measures

Measure	Placebo n=105 Participants Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Etanercept n=106 Participants Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a more than 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Escape: Etanercept Participants with a \> 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, escaped to etanercept 0.8 mg/kg once a week up to week 12.
Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) at Week 12	13 percentage of participants	53 percentage of participants	—

SECONDARY outcome

Timeframe: Baseline and week 12

Population: Intent-to-treat population with available CDLQI data at baseline

The Children's Dermatology Life Quality Index (CDLQI) was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (Not at all) to 3 (Very much). The total score ranges from 0 to 30, with lower scores indicating better quality of life. If participants were ≥ 13 years old, the text instrument was completed by the participants themselves. Participants ≥ 8 but < 13 years old used the cartoon version of the instrument and participants ≤ 7 years old used the cartoon version of the instrument completed with help from the parents or caregivers.

Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline Value * 100.

Participants who entered the escape arm or who had missing data at week 12 were considered to have 0% improvement from baseline.

Outcome measures

Measure	Placebo n=102 Participants Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Etanercept n=100 Participants Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a more than 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Escape: Etanercept Participants with a \> 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, escaped to etanercept 0.8 mg/kg once a week up to week 12.
Percent Improvement From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 12	17.5 percent improvement Standard Error 8.3	52.3 percent improvement Standard Error 6.1	—

SECONDARY outcome

Timeframe: Baseline and week 12

Population: Intent-to-treat population

The percentage of participants who achieved 90% or greater improvement from baseline in PASI score after 12 weeks of treatment. The PASI score is a combination of the intensity of psoriasis, assessed by erythema (reddening), induration (plaque thickness) and desquamation (scaling) scored on a scale from 0 (none) to 4 (very severe), together with the percentage of the area affected, rated on a scale from 0 (no involvement) to 6 (90% to 100% involvement). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Participants who entered the escape arm or had missing data at week 12 were considered non-responders.

Outcome measures

Measure	Placebo n=105 Participants Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Etanercept n=106 Participants Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a more than 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Escape: Etanercept Participants with a \> 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, escaped to etanercept 0.8 mg/kg once a week up to week 12.
Percentage of Participants Achieving a ≥ 90% Improvement in PASI Score (PASI 90) at Week 12	7 percentage of participants	27 percentage of participants	—

SECONDARY outcome

Timeframe: 12 weeks

Population: The safety population included all participants who received at least 1 dose of study drug.

The severity assessment for adverse events and infections was done using the Common Toxicity Criteria (CTC) Version 2.0, where Grade 0 = no toxicity, Grade 1 = mild toxicity, Grade 2 = moderate toxicity, Grade 3 = severe toxicity, Grade 4 = life-threatening toxicity.

Serious adverse events were any events that suggested a significant hazard or side effect, regardless of the investigator's or sponsor's opinion on the relationship to study medication. These included, but were not limited to, events at any dose that were fatal, life threatening, required in-patient hospitalization or prolonged hospitalization, were a persistent or significant disability/incapacity, or were a congenital abnormality/birth defect. Medical events that jeopardized a participant, required intervention to prevent one of the above outcomes, or resulted in urgent investigation could be considered serious.

Outcome measures

Measure	Placebo n=105 Participants Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Etanercept n=106 Participants Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a more than 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Escape: Etanercept n=32 Participants Participants with a \> 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, escaped to etanercept 0.8 mg/kg once a week up to week 12.
Number of Participants With Adverse Events During the Double-blind Treatment Period Any adverse event	62 Participants	68 Participants	16 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Non-infectious adverse event	46 Participants	42 Participants	9 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Infection	33 Participants	50 Participants	9 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Serious non-infectious adverse event	0 Participants	0 Participants	0 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Serious infection	0 Participants	0 Participants	0 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Death	0 Participants	0 Participants	0 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Grade 3 non-infectious adverse event	3 Participants	0 Participants	0 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Grade 3 infection	0 Participants	0 Participants	0 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Non-infectious AE leading to withdrawal from Study	0 Participants	1 Participants	0 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Infection leading to withdrawal from Study	0 Participants	0 Participants	0 Participants
Number of Participants With Adverse Events During the Double-blind Treatment Period Injection site reaction	5 Participants	7 Participants	1 Participants

SECONDARY outcome

Timeframe: Day 1 (predose), week 12, week 24, and week 48

Population: Participants assigned to etanercept at any time during the study, with available data. Week 12 excludes participants assigned to placebo who escaped to etanercept. Week 48 includes participants randomized to etanercept at week 36 and remaining on etanercept to week 48. Participants randomized to placebo and retreated with etanercept are excluded.

Serum concentrations for etanercept were measured by using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 0.627 ng/mL.

Outcome measures

Measure	Placebo n=208 Participants Participants randomized to receive placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a \> 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Etanercept Participants randomized to receive 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a more than 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.	Escape: Etanercept Participants with a \> 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, escaped to etanercept 0.8 mg/kg once a week up to week 12.
Etanercept Serum Concentration Day 1	1.50 ng/mL Standard Deviation 3.13	—	—
Etanercept Serum Concentration Week 12	1614 ng/mL Standard Deviation 828	—	—
Etanercept Serum Concentration Week 24	2104 ng/mL Standard Deviation 1255	—	—
Etanercept Serum Concentration Week 48	1650 ng/mL Standard Deviation 1126	—	—

Adverse Events

Double-blind Period: Placebo

Serious events: 0 serious events

Other events: 44 other events

Deaths: 0 deaths

Double-blind Period: Etanercept 0.8 mg/kg QW

Serious events: 0 serious events

Other events: 59 other events

Deaths: 0 deaths

Double-blind Period: Escape to Etanercept 0.8 mg/kg QW

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Open-label Period: Etanercept 0.8 mg/kg QW

Serious events: 0 serious events

Other events: 174 other events

Deaths: 0 deaths

Open-label Period Incomplete Response: Etanercept 0.8 mg/kg QW

Serious events: 0 serious events

Other events: 54 other events

Deaths: 0 deaths

Withdrawal Period: Placebo

Serious events: 0 serious events

Other events: 23 other events

Deaths: 0 deaths

Withdrawal Period: Etanercept 0.8 mg/kg QW

Serious events: 0 serious events

Other events: 26 other events

Deaths: 0 deaths

Re-treatment Period: Placebo/Etanercept 0.8 mg/kg QW

Serious events: 0 serious events

Other events: 9 other events

Deaths: 0 deaths

Re-treatment Period: Etanercept / Etanercept 0.8 mg/kg QW

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Measure	Double-blind Period: Placebo n=105 participants at risk Participants received placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12).	Double-blind Period: Etanercept 0.8 mg/kg QW n=106 participants at risk Participants received 0.8 mg/kg etanercept administered by subcutaneous injection once a week (QW) during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12).	Double-blind Period: Escape to Etanercept 0.8 mg/kg QW n=32 participants at risk Participants with a \> 50% worsening (ie, increase) in PASI score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or with an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, escaped to etanercept 0.8 mg/kg once a week up to week 12.	Open-label Period: Etanercept 0.8 mg/kg QW n=208 participants at risk Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).	Open-label Period Incomplete Response: Etanercept 0.8 mg/kg QW n=59 participants at risk Participants who did not achieve PASI 50 at week 24 or PASI 75 at week 36 continued to receive open-label etanercept 0.8 mg/kg QW plus optional topical standard-of-care therapy (low-to-moderate-potency topical corticosteroids) until week 48.	Withdrawal Period: Placebo n=69 participants at risk At week 36, participants with a PASI 75 response were re-randomized to receive placebo once a week for 12 weeks in the double-blind, withdrawal period (weeks 37 to 48) or until relapse (loss of PASI 75 response).	Withdrawal Period: Etanercept 0.8 mg/kg QW n=68 participants at risk At week 36, participants with a PASI 75 response were re-randomized to receive 0.8 mg/kg etanercept once a week for 12-weeks in the double-blind, withdrawal period (weeks 37 to 48) or until relapse (loss of PASI 75 response).	Re-treatment Period: Placebo/Etanercept 0.8 mg/kg QW n=30 participants at risk Participants randomized to placebo at week 36 who relapsed (loss of PASI 75 response) resumed open-label treatment with 0.8 mg/kg etanercept once a week until week 48.	Re-treatment Period: Etanercept / Etanercept 0.8 mg/kg QW n=12 participants at risk Participants randomized to etanercept at week 36 who relapsed (loss of PASI 75 response) resumed open-label treatment with 0.8 mg/kg etanercept once a week until week 48.
Gastrointestinal disorders Abdominal Pain	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 6/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal Pain Upper	1.9% 2/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 3/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.3% 11/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.4% 2/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Diarrhoea	3.8% 4/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.94% 1/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 9/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.8% 4/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.4% 1/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Nausea	2.9% 3/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 3/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.2% 13/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.4% 1/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Vomiting	1.9% 2/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.8% 4/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.2% 15/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.2% 6/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.4% 1/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Injection Site Bruising	3.8% 4/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.94% 1/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.8% 12/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Injection Site Pain	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.9% 2/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 6/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Injection Site Reaction	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.9% 2/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.4% 7/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.4% 1/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Pyrexia	0.95% 1/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.9% 2/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.8% 12/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.7% 1/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Immune system disorders Seasonal Allergy	0.95% 1/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.94% 1/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.9% 4/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.7% 1/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Body Tinea	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.4% 3/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.4% 1/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Conjunctivitis Viral	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.48% 1/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Ear Infection	0.95% 1/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.9% 2/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 9/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.4% 2/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.4% 1/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Folliculitis	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 6/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastroenteritis	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.7% 6/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.1% 1/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.2% 13/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.8% 4/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.3% 1/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Gastroenteritis Viral	2.9% 3/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.9% 2/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.2% 13/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.5% 5/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.4% 1/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Influenza	1.9% 2/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.5% 8/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	11.1% 23/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.4% 2/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.3% 1/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Nasopharyngitis	8.6% 9/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.5% 8/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	18.8% 39/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	20.3% 12/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.3% 7/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Otitis Media	1.9% 2/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.8% 10/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.5% 5/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.3% 1/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Pharyngitis	3.8% 4/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.9% 2/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.2% 13/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.5% 5/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Pharyngitis Streptococcal	0.95% 1/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 3/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.1% 1/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.2% 17/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.2% 6/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Sinusitis	0.95% 1/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.94% 1/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.1% 1/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.8% 12/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.7% 2/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.3% 1/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Skin Infection	0.95% 1/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.94% 1/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.1% 1/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.8% 8/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.8% 4/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Upper Respiratory Tract Infection	11.4% 12/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	17.0% 18/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.5% 4/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	30.8% 64/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	42.4% 25/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.1% 7/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	10.0% 3/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	25.0% 3/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.7% 5/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.8% 10/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.8% 4/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin Papilloma	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.9% 2/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.2% 2/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.2% 13/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.4% 1/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Dizziness	0.95% 1/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.7% 5/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.8% 8/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Headache	12.4% 13/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.2% 14/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.1% 1/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	20.2% 42/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	20.3% 12/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.8% 6/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Cough	1.9% 2/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.8% 4/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.1% 19/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.8% 4/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.2% 5/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Nasal Congestion	2.9% 3/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 3/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.1% 1/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.2% 17/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.7% 2/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Pharyngolaryngeal Pain	5.7% 6/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.94% 1/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.1% 1/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	9.6% 20/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	15.3% 9/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 3/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.5% 1/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	1.9% 2/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.8% 3/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.1% 1/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 9/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.5% 5/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Acne	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	3.1% 1/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.8% 10/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	6.8% 4/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.9% 2/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Guttate Psoriasis	0.95% 1/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.94% 1/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	1.9% 4/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/105 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.94% 1/106 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/32 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	2.4% 5/208 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	5.1% 3/59 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/69 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/68 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/30 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/12 • Double-blind treatment period: 12 weeks Escape to etanercept: from time of escape to week 12 (maximum of 8 weeks) Open-label treatment period: 24 weeks Incomplete response: From date of incomplete response to week 48 (maximum of 24 weeks) Withdrawal Period: 12 weeks Re-treatment Period: From date of re-treatment to week 48 (maximum of 8 weeks) Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Email: medinfo@amgen.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
• Publication restrictions are in place

Restriction type: OTHER